However, to date, most studies [7, 12–15] have focused on the relationships between ER expression and survival prognosis; very few studies investigate the influence of ER expression status on the outcome of treatment for NSCLC, which may contribute to establishing ER expression as a useful biomarker for clinical treatment decision. Here, ESR1 is linked to non-small cell lung carcinoma.